Member Info for Fruitsnveg

I have needed one Greenlabel, and I agree with you.

We could. Anything is possible and it's a timely reminder.
I wonder though if our method (inhaled directly into the lung) will prove more effective than Redhill's orally administered drug? One wonders.

I think you'll see Tony's post on the RNS used word 'suggest', rather than 'predict' . IMO anything that adds another flavour to the conversation is welcome.

Doc,
If I may, I would say here have been too many threads about cashflow, not charts, in the last week. Although it's not an art form I practice (I wish I had learned), I genuinely value the chart input here from Tony et al. Even if like me, you don't understand much of the jargon, or you simply don't believe, I find it still gives a strong flavour of 'wind direction' and a good indication of what may potentially happen, because it is based on real data. I'm sure Tony would say it's not an exact science nor is it intended to be (would you agree Tony?). I'm sure it helps some to better time buys and sells and I like to know how chartists view events.
The British weather is fickle beast - the BBC sometimes get the forecast wrong because things are always in flux, but I still check it religiously everyday and dress accordingly.

Thanks Joey for posting. I'm wondering, in hindsight, if some licencing agreements have already been conditionally "secured" for want of a better word (conditional on P3 data/results). I find it increasingly unlikely that a Head of CMC would have started in September without some impetus like that. Thoughts?

Agree Ndn71. If Astra Zeneca were willing to licence the drug in 2016 for a cool $232 million, I rest my case....

I notice today that hot on the heels of Yahoo Finance, we have another article from an even more dubiously researched due at OS (I won't insert a link to the article here because it's just to plagiarised and well, samey), again alerting investors to the company's cash flow situation. I expect MF to roll out the same drivel this week, tomorrow perhaps. Anyway, the point is - prepare yourselves for an onslaught of "Yeah but the cash situation" articles .... With the usual lack of flair and wit, they seem to be targeting that angle above all else. Yawn.

I haven't seen it Andy but I have long thought the route they have taken was the best one (for shareholders). "Masterclass in jabbering twaddle" - love it.

It's the well trodden "considering all the factors discussed in this article, we are not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Taking a deeper dive, we've spotted 3 warning signs for Synairgen (or...insert company name they are shorting here) you should be aware of, and 1 of them is significant. etc etc.".

Just exquisite. Lol.

Read the article. No one is suggesting we remain safe. The quote relates to our global situation.
The author suggests UK gov is conning itself if it thinks ridding one country (ours) of Covid will stop the pandemic, amongst other salient and well researched points. -> Which makes the case that Synairgen's expected approval in Q1 will not be too late. The BB's fearmongers will be back soon to tell us Q1 is too late. It's not.

https://www.theguardian.com/commentisfree/2021/sep/12/the-winter-covid-plan-will-be-marked-by-delay-confusion-and-ignorance-sound-familiar

"We are not safe from Covid-19 until we are all safe."

Thanks for posting Blessed22. It 's beginning to feel very real now! Great article. Perhaps it will bring a flurry of new PI activity on Monday am...

It all depends on what type of overtures are made and whether they are friendly/acceptable, or not.

He started this role at Synairgen this month, per his LinkedIn details.

The results and how well they future-proof Synairgen's place in the wider respiratory market will dictate the price. Nothing else. It could be £5 or it could be £50. Don't underestimate the worth and applicability of this drug. Wait for the data and wait for the BOD to report, most importantly.

Prion25, I think that's a good idea ref RM.

The cause of long COVID-19 has eluded scientists, but the UAMS team's discovery sheds important new light on the molecular-level mechanisms behind it:
https://news.uams.edu/2021/09/09/uams-research-team-finds-potential-cause-of-covid-19-long-haulers/

For those who have been following the ACE 2 science (not me, but I think there's still a few on the BB)...a new study with new findings.

I have no idea CW25, but they have invested in the same companies before (Arcam SB, a swedish company. They then both sold their shares to GE Electric who wanted to boost their control of the company). Never a dull day.

CW25, Clingen & SNG shares today:

https://news.sky.com/story/activist-elliott-floats-break-up-of-pharma-services-group-clinigen-12404003

We have a signed access agreement with Clinigen.

Anyone else smell something off here?

Goldforefinger,
"Poly know a buyout/takeover is on the cards."
Do you think they are "representing"?